Logan Coy Related postsSubstudy ASPEN-09-03: A Single-arm Phase 2 Study of Evorpacept with Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (ASPEN-09-03), Protocol AT148009September 10, 2026An Open-Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients with Lymphoid Malignancies (the OPAL Study)September 11, 2026Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)September 11, 2026 Previous postA Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation Study of Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung CancerNext postA First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid Tumors